‘Treg’ Startup Sonoma Expands with Plans for Manufacturing Plant


Preclinical biotech company Sonoma Biotherapeutics has announced plans to build an 83,000-square-foot manufacturing and research center on Seattle’s waterfront.

The new facility will be used to develop and produce Sonoma’s experimental medicines based on regulatory T cells (Tregs) with plans to include capabilities for cell selection, genetic modification, and automated manufacturing.

“Seattle has an established legacy of delivering many firsts in the cell therapy field for cancer, and we are building upon those insights to advance our pipeline of engineered Treg therapies for autoimmune and inflammatory diseases,” said Sonoma Biotherapeutics CEO and president Jeffrey Bluestone.